{"page":{"totalFilteredElements":71},"studies":[{"active":true,"description":"
Pre-Operative Treatment in rEseCTable cOlon canceR
(PROTECTOR/FIRE-10; AIO KRK0620; IAG-VO-0323)
Prospective, randomized, open, multicenter Phase III trial
to investigate the efficacy preoperative systemic therapy in
advanced colon cancer
","eudractNumber":"2023-508076-11-00","id":11330,"indications":[{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-04-01T10:43:27+02:00","shortTitle":"PROTECTOR/ Fire-10","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTICD20 X ANTI-CD3 BISPECIFIC ANTIBODY, VERSUS INVESTIGATOR’S CHOICE IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-1)
","eudractNumber":"2022-502660-20","id":9250,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06091254","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-12-10T08:58:51+01:00","shortTitle":"R1979-HM-2298 (OLYMPIA-1)","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Ropeginterferon alfa-2b bei Patienten mit Polycythemia\nvera","eudractNumber":null,"id":11329,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-09-15T10:54:42+02:00","shortTitle":"ROPE","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Eine internationale prospektive Studie zum klinischen Hochrisiko-Medulloblastom (HR-MB) bei Patienten, die älter als 3 Jahre sind","eudractNumber":"2018-004250-17","id":9623,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"}],"mutations":[{"name":"TP53","id":"mt_24"},{"name":"MYC (c-MYC)","id":"mt_73"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-04-19T10:36:51+02:00","shortTitle":"SIOP High-Risk Medulloblastoma","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"Internationale, prospektive \"Umbrella\" Studie incl. einer randomisierten Phase III-Studie zur Frage der Nichtunterlegenheit von 3 Kursen Hochdosis-Chemotherapie verglichen mit fokaler Radiotherapie + Standard-Chemotherapie in der Konsolidierung nach einer konventionellen Induktions-Chemotherapie für Kinder mit einem ATRT im Alter von 12 - 35 Monaten zum Zeitpunkt der Bestrahlung","eudractNumber":"2018-003335-29","id":4960,"indications":[{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped3","name":"Hirntumore (Tumore des zentralen Nervensystems)"}],"mutations":[{"name":"Others","id":"mt_8"}],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2021-07-22T11:28:30+02:00","shortTitle":"SIOPe ATRT-01","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (SUCCESSOR-1)

CA057-001

","eudractNumber":"2023-509859-13","id":10285,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05519085","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2025-03-13T15:17:15+01:00","shortTitle":"SUCCESSOR-1","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"},{"id":"tl_3","name":"Drittlinie"},{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Therapie refraktärer Virusinfektionen nach allogener Stammzelltransplantation mit multispezifischen T-Zellen gegen CMV, EBV und ADV: eine Phase III, prospektive, multizentrische klinische Studie
DRKS00018985
","eudractNumber":"2018-000853-29","id":8206,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04832607","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2022-02-01T15:11:32+01:00","shortTitle":"TRACE","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"
A Phase 3 Randomized Study Comparing JNJ-79635322 and 
an anti-BCMA AxCD3 Bispecific Antibody in Participants with Relapsed or Refractory Multiple Myeloma who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
","eudractNumber":"2025-522007-18","id":11964,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT07258511","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2026-06-23T12:17:39+02:00","shortTitle":"Trilogy-4","therapeutical":true,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Effekt von hochdosiertem Vitamin D3 auf die 28-Tages-Mortalität bei erwachsenen kritisch kranken Patienten mit schwerem Vitamin D Mangel: eine multizentrische, Placebo-kontrollierte, doppelblinde Phase III Studie
Eudra-CT: 2016-002460-13
","eudractNumber":"2024-514556-32-00","id":8204,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-03-20T13:38:53+01:00","shortTitle":"VITDALIZE","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"
INTERNATIONAL EURO EWING TRIAL FOR TREATMENT OPTIMISATION IN PATIENTS WITH EWING SARCOMA
","eudractNumber":"2019-004153-93","id":9005,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped4","name":"Weitere solide Tumore"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-12-04T08:59:33+01:00","shortTitle":"i EuroEwing","therapeutical":true,"therapyLines":[{"id":"tl_3","name":"Drittlinie"}]}]}